Health Condition 1: L409- Psoriasis, unspecified
Conditions
Interventions
Intervention1: 1. Safuf-i-Musaffi Khas
2. Ravghan-i-Hina: 1. Safuf-i-Musaffi Khas: Dosage Form: Safuf(Powder), Dose: 5gm OD, Mode of administration: Oral, Composition of Safuf-i-Musaffi Khas: Aamla Kh
Sponsors
National Research Institute of Unani Medicine for Skin Disorders, Hyderabad
Eligibility
Inclusion criteria
Inclusion criteria: The participants will be included in the study on the basis of the following criteria: 1. Participants of any sex aged between 18 to 60 years. 2. Patients clinically diagnosed with Taqashshur al-Jild (Psoriasis). 3. Patients with a Psoriasis Area and Severity Index (PASI) score equal to or more than 10%. 4. Patients with a minimum psoriasis duration of at least six months. 5. Patients who have failed or are intolerant to at least one conventional systemic therapy for psoriasis. 6. Patients with a Dermatology Life Quality Index (DLQI) score more than 10. 7. Participants willing to provide written informed consent and comply with study procedures.
Exclusion criteria
Exclusion criteria: The following patients will be excluded: 1. Participants aged below 18 years or above 60 years. 2. Known cases of significant pulmonary, cardiovascular, hepatic, renal dysfunction, malignancy, HIV/AIDS, or other systemic diseases. 3. Pregnant or lactating women. 4. Patients unwilling to attend the clinical trial. 5. Patients with other skin conditions, such as eczema or chronic dermatitis, that could interfere with psoriasis assessment. 6. Patients currently taking medications that interfere with study drug metabolism or psoriasis severity. 7. Patients with a history of alcohol or drug abuse. 8. Patients with uncontrolled psychiatric disorders. 9. Patients with known hypersensitivity to any component of the study medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical assessment will be done at baseline visit and at each follow-up visit 2nd, 4th and 8th weeks and the assessment of response to treatment will be made on the basis of the change in PASI Score after 8th weeks of therapy. For the efficacy of the test drug, 25% change in appearance and symptomatic relief will be considered significant.Timepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Photographic Assessment: Digital photography of all lesions will be done using conditions (fixed room, fixed lighting & fixed camera settings) at baseline & 8th week.Timepoint: 8 weeks;Improvement in DLQI from baselineTimepoint: 8 weeks;Improvement in IGA from baselineTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactDR WALIULLAH
National Research Institute of Unani Medicine for Skin Disorders
Outcome results
None listed